Specialised Therapeutics Australia, of Melbourne, Australia, and Helsinn Group, of Lugano, Switzerland, said the Therapeutic Goods Administration approved Akynzeo (netupitant/palonosetron) to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy (CINV).